New nucleoside/nucleotide backbone options: A review of recent studiesRUANE, Peter J; DEJESUS, Edwin.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 37, pp S21-S29, issn 1525-4135, SUP1Conference Paper

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsSQUIRES, Kathleen E; YOUNG, Benjamin; DEJESUS, Edwin et al.AIDS (London). 2010, Vol 24, Num 13, pp 2019-2027, issn 0269-9370, 9 p.Article

Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once-Daily Abacavir/Lamivudine/Zidovudine and Tenofovir DF (Study COL40263)ROSS, Lisa; ELION, Richard; BELINDA HA et al.AIDS research and human retroviruses. 2009, Vol 25, Num 7, pp 665-672, issn 0889-2229, 8 p.Article

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: Results of the Ziagen Once Daily in Antiretroviral Combination StudyMOYLE, Graeme J; DEJESUS, Edwin; CAHN, Pedro et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 38, Num 4, pp 417-425, issn 1525-4135, 9 p.Article

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trialGALLANT, Joel E; STASZEWSKI, Schlomo; POZNIAK, Anton L et al.JAMA, the journal of the American Medical Association. 2004, Vol 292, Num 2, pp 191-201, issn 0098-7484, 11 p.Article

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyLALEZARI, Jacob P; ERON, Joseph J; NELSON, Emily L et al.AIDS (London). 2003, Vol 17, Num 5, pp 691-698, issn 0269-9370, 8 p.Article

Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjectsDEJESUS, Edwin; WALD, Anna; WARREN, Terri et al.The Journal of infectious diseases. 2003, Vol 188, Num 7, pp 1009-1016, issn 0022-1899, 8 p.Article

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsCOOPER, David A; HEERA, Jayvant; SAAG, Michael et al.AIDS (London). 2014, Vol 28, Num 5, pp 717-725, issn 0269-9370, 9 p.Article

Antiviral Activity, Safety, and Pharmacokinetics/ Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1―Positive AdultsRUANE, Peter J; DEJESUS, Edwin; YALE, Kitty et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 63, Num 4, pp 449-455, issn 1525-4135, 7 p.Article

Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adultsMIN, Sherene; SLOAN, Louis; PISCITELLI, Stephen et al.AIDS (London). 2011, Vol 25, Num 14, pp 1737-1745, issn 0269-9370, 9 p.Article

Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected PatientsROSS, Lisa L; WEINBERG, Winkler G; DEJESUS, Edwin et al.AIDS research and human retroviruses. 2010, Vol 26, Num 4, pp 407-417, issn 0889-2229, 11 p.Article

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 InfectionCOOPER, David A; HEERA, Jayvant; REEVES, Jacqueline D et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 803-813, issn 0022-1899, 11 p.Article

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 TrialSULEIMAN, Jamal; ZINGMAN, Barry S; WALMSLEY, Sharon et al.The Journal of infectious diseases. 2010, Vol 201, Num 4, pp 590-599, issn 0022-1899, 10 p.Article

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patientsGALLANT, Joel E; WINSTON, Jonathan A; DEJESUS, Edwin et al.AIDS (London). 2008, Vol 22, Num 16, pp 2155-2163, issn 0269-9370, 9 p.Article

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsDEJESUS, Edwin; BERGER, Daniel; MCCOLL, Damian et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 1, pp 1-5, issn 1525-4135, 5 p.Article

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patientsGATHE, Joseph C; IVE, Prudence; WOOD, Robin et al.AIDS (London). 2004, Vol 18, Num 11, pp 1529-1537, issn 0269-9370, 9 p.Article

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected AdultsJACOBSON, Jeffrey M; KURITZKES, Daniel R; GODOFSKY, Eliot et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 2, pp 450-457, issn 0066-4804, 8 p.Article

Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1―Infected PatientsDEJESUS, Edwin; YOUNG, Benjamin; MCCOLL, Damian et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 2, pp 163-174, issn 1525-4135, 12 p.Article

Virologic and immunologic activity of Peglntron in HIV diseaseANGEL, Jonathan B; GREAVES, Wayne; JIANMIN LONG et al.AIDS (London). 2009, Vol 23, Num 18, pp 2431-2438, issn 0269-9370, 8 p.Article

Adherence to Enfuvirtide and Its Impact on Treatment EfficacyROCKSTROH, Jürgen; DEJESUS, Edwin; THOMMES, James et al.AIDS research and human retroviruses. 2008, Vol 24, Num 2, pp 141-148, issn 0889-2229, 8 p.Article

Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionGULICK, Roy M; LALEZARI, Jacob; MONTANA, John B et al.The New England journal of medicine. 2008, Vol 359, Num 14, pp 1429-1441, issn 0028-4793, 13 p.Article

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients : 144-Week AnalysisARRIBAS, Jose R; POZNIAK, Anton L; TOOLE, John J et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 47, Num 1, pp 74-78, issn 1525-4135, 5 p.Article

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients : Virologic, immunologic, and morphologic changes-A 96-week analysisPOZNIAK, Anton L; GALLANT, Joel E; CHENG, Andrew K et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 5, pp 535-540, issn 1525-4135, 6 p.Article

Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, seal)SOSA, Nestor; HILL-ZABALA, Christina; DEJESUS, Edwin et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 40, Num 4, pp 422-427, issn 1525-4135, 6 p.Article

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyLAWITZ, Eric; SULKOWSKI, Mark S; LIM, Joseph K et al.Lancet (British edition). 2014, Vol 384, Num 9956, pp 1756-1765, issn 0140-6736, 10 p.Article